Lamotrigine Sustained Release Tablet for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional lamotrigine tablet formulations provide immediate release, leading to cyclical plasma concentration profiles with peaks and troughs, which can result in breakthrough seizures and adverse events, particularly in epilepsy treatment, and do not effectively manage chronic conditions like schizophrenia and multiple sclerosis.
Innovation Solution
Development of a sustained release formulation of lamotrigine that releases the drug approximately 2 to 20 hours after administration, preferably 6 to 16 hours, to maintain therapeutic levels with reduced peak plasma concentrations and minimize adverse events, achieved through the use of release-retarding polymers and coatings that control the drug's release in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional immediate release tablet formulations are used, then the drug is rapidly absorbed and therapeutic effect is achieved quickly, but cyclical plasma concentration profiles with peaks and troughs occur leading to breakthrough seizures and adverse events
Solution Approach 1:
The tablet is segmented into multiple functional layers: an immediate release layer for rapid initial absorption and a sustained release layer for prolonged drug delivery. This segmentation allows the formulation to provide both quick therapeutic onset and stable plasma concentrations over time, resolving the contradiction between fast absorption and concentration stability.
Solution Approach 2:
The invention changes the release rate parameter by incorporating sustained release materials such as hydroxypropyl methylcellulose (HPMC) with varying viscosity grades. By adjusting the polymer concentration and viscosity parameters, the formulation controls the drug release kinetics to maintain stable plasma levels while still achieving therapeutic effects.
2Speed
If conventional immediate release formulations are used, then peak plasma concentrations are achieved quickly, but adverse events increase due to high peak levels
Solution Approach 1:
The tablet structure separates the immediate release function (providing quick onset) from the sustained release function (controlling peak levels). The immediate release layer ensures rapid initial absorption for quick onset of action, while the sustained release layer modulates the release rate to prevent excessive peak concentrations that cause adverse events.
Solution Approach 2:
The formulation creates a periodic release pattern where the immediate release layer provides an initial drug pulse followed by sustained release from the second layer. This periodic action pattern maintains drug levels within the therapeutic window, avoiding the harmful high peaks associated with conventional immediate release formulations.
3Reliability
If conventional formulations require multiple daily doses to maintain therapeutic levels, then plasma concentration stability is improved, but patient compliance decreases
Solution Approach 1:
The invention merges the immediate release and sustained release formulations into a single combination tablet. This unified formulation delivers both rapid initial absorption and prolonged drug release in one dosage form, allowing once-daily administration while maintaining stable plasma concentrations, thereby improving patient compliance without sacrificing concentration stability.
Solution Approach 2:
The sustained release layer ensures continuous drug release over an extended period (12-24 hours), maintaining therapeutic plasma levels throughout the dosing interval. This continuous action eliminates the need for multiple daily doses while preserving plasma concentration stability, making the treatment regimen easier to follow.
4Object-generated harmful factors
If sustained release formulations are developed to reduce peak concentrations, then adverse events are minimized, but the complexity of formulation increases
Solution Approach 1:
While segmentation into layers increases structural complexity, it enables the formulation to minimize adverse events by controlling release kinetics. The layered structure, though more complex than single-layer tablets, provides precise control over drug release patterns, reducing peak concentrations and associated side effects.
Solution Approach 2:
The formulation uses composite materials combining immediate release excipients with sustained release polymers (HPMC of various viscosities). This composite approach allows tailoring the release profile to minimize adverse events while managing formulation complexity through the use of well-characterized commercial polymer materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release formulation provides consistent drug levels, reduces adverse events, enhances patient compliance, and effectively manages chronic conditions like epilepsy, schizophrenia, and multiple sclerosis by maintaining therapeutic concentrations with a lower rise in plasma levels, thus improving treatment outcomes.
Implementation Method 1
The sustained release formulation... releases the drug approximately 2 to 20 hours after administration... achieved through the use of release-retarding polymers and coatings that control the drug's release in the gastrointestinal tract
Data Source
AI summary
A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.